Grimminger, Peter P., Schneider, Paul M., Metzger, Ralf, Vallboehmer, Daniel, Danenberg, Kathleen D., Danenberg, Peter V., Hoelscher, Arnulf H. and Brabender, Jan (2010). The prognostic role of Bcl-2 mRNA expression in curatively resected non-small cell lung cancer (NSCLC). Lung Cancer, 70 (1). S. 82 - 88. CLARE: ELSEVIER IRELAND LTD. ISSN 1872-8332

Full text not available from this repository.

Abstract

Background: The effect of the apoptosis related gene Bcl-2 in the pathogenesis in NSCLC remains poorly investigated. Hence the aim of this study was to explore the potential role of Bcl-2 mRNA expression as a prognostic biomarker in patients with curatively resected NSCLC. Methods: 91 tumor and matching normal tissue samples from patients with NSCLC were analyzed using a quantitative real-time RT-PCR method. The relative Bcl-2 mRNA expression was measured using beta-actin as a reference gene. 45 of the 91 patients had stage I tumors (49%), 19 had stage 11 (21%) and 27 had stage IIIa (30%). Squamous cell carcinoma was found in 43 patients (47%), adenocarcinoma in 33 (36%) and in large cell carcinoma in 15(17%) of the patients. Results: Bcl-2 mRNA expression was detected in 83 (91%) of the investigated tumor samples and in 74 (81%) of the normal lung tissue. The median gene expression was 0.147 in tumor tissue and 0.144 in matching normal lung tissue (p = n.s., Wilcoxon Test). No associations were seen between the tumorous Bcl-2 mRNA expression levels and clinical or histopathologic parameters such as gender, tumor size, TNM stadium and grading, but with tumor histology and smoking. With a follow-up of 85.9 months, the median survival time was 59.7 months. Bcl-2 mRNA expression was significantly associated with patients prognosis (p = 0.013, log-rank test). Multivariate regression analysis revealed Bcl-2 expression status and tumor stage as independent prognostic factor. Conclusions: Bcl-2 expression in NSCLC is not associated with the pathogenesis of this disease. Our data suggests that Bcl-2 mRNA expression plays a crucial role in the biological behavior of NSCLCs. Quantitation of Bcl-2 expression improves estimation of prognosis and appears to identify patients who will benefit from intensive adjuvant therapy. (C) 2009 Elsevier Ireland Ltd. All rights reserved.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Grimminger, Peter P.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schneider, Paul M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Metzger, RalfUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Vallboehmer, DanielUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Danenberg, Kathleen D.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Danenberg, Peter V.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hoelscher, Arnulf H.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Brabender, JanUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-495966
DOI: 10.1016/j.lungcan.2009.12.013
Journal or Publication Title: Lung Cancer
Volume: 70
Number: 1
Page Range: S. 82 - 88
Date: 2010
Publisher: ELSEVIER IRELAND LTD
Place of Publication: CLARE
ISSN: 1872-8332
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
CHI-SQUARE STATISTICS; PROTOONCOGENE BCL-2; PROSTATE-CANCER; BREAST-CANCER; SURVIVAL; P53; PROTEIN; APOPTOSIS; MARKERS; CARCINOMAMultiple languages
Oncology; Respiratory SystemMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/49596

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item